In a patient with sarcoidosis in remission who is tapering mycophenolate mofetil and has had fever for two days while in India, which infections should be ruled out?

Fever During MMF Taper in Sarcoidosis Patient in India: Infections to Rule Out

In a patient tapering mycophenolate mofetil for sarcoidosis in remission who develops fever in India, you must urgently rule out tuberculosis (including atypical mycobacteria), bacterial sepsis/bacteremia, cytomegalovirus, herpes zoster, fungal infections (especially Candida and Aspergillosis), and opportunistic infections including Pneumocystis jirovecii.

Priority Infectious Workup

The FDA label for MMF explicitly warns that patients on this medication face increased risk of serious, life-threatening infections that can be fatal 1. The immunosuppression from MMF creates specific vulnerability patterns you must address systematically.

Highest Priority: Tuberculosis and Atypical Mycobacteria

Start with TB evaluation immediately. The FDA specifically identifies tuberculosis and atypical mycobacterial infections as having "higher frequency" in MMF-treated patients 1. In India, with high TB prevalence, this becomes your first concern:

• Obtain chest X-ray looking for infiltrates, cavitation, or miliary pattern
• Send sputum for AFB smear and GeneXpert MTB/RIF
• Consider TB-IGRA or PPD (though may be falsely negative with immunosuppression)
• Blood cultures for mycobacteria if disseminated disease suspected

Second Priority: Bacterial Infections

The FDA data shows bacterial infections are common and serious in MMF patients 1. Focus on:

• Bacteremia/sepsis - Blood cultures before any antibiotics (this is the top specific infection risk 2)
• Urinary tract infection/pyelonephritis - Urinalysis and urine culture (second most common specific infection 2)
• Pneumonia - Chest imaging and respiratory cultures if respiratory symptoms present

Third Priority: Viral Infections

MMF specifically increases risk of several viral infections 1:

• Herpes zoster - Examine for vesicular rash in dermatomal distribution (third most common specific infection 2)
• CMV viremia/disease - CMV PCR and consider tissue-invasive disease if organ symptoms present
• Hepatitis B/C reactivation - Check HBV DNA and HCV RNA if patient has known infection history
• BK virus - Particularly if any renal dysfunction (polyomavirus-associated nephropathy)

Fourth Priority: Fungal Infections

The FDA warns about yeasts and other fungal infections causing serious tissue and blood infections 1:

• Candida - Blood cultures for fungemia, assess for mucocutaneous or disseminated disease
• Aspergillus/Mucor - Consider if respiratory symptoms; galactomannan assay, beta-D-glucan
• Cryptococcus - Serum cryptococcal antigen, especially if any neurological symptoms
• Endemic mycoses - Consider histoplasmosis or other regional fungi based on exposure

Fifth Priority: Opportunistic Infections

• Pneumocystis jirovecii pneumonia (PCP) - If respiratory symptoms, obtain induced sputum or BAL for PCP staining
• Progressive Multifocal Leukoencephalopathy (PML) - If any neurological symptoms (weakness, apathy, confusion, ataxia), obtain brain MRI and CSF JC virus PCR 1

Critical Clinical Context

The infection risk is dose-dependent and cumulative 2. Since your patient is tapering MMF, they remain at elevated risk even with dose reduction. The FDA reports that neutropenia (which increases infection susceptibility further) occurs in up to 2% of patients and is most common 31-180 days post-treatment initiation 1.

Immediate Laboratory Assessment

• Complete blood count with differential (check for neutropenia: ANC < 1.3 × 10³/µL requires MMF dose adjustment 1)
• Comprehensive metabolic panel
• Blood cultures (bacterial and fungal)
• Urinalysis and culture
• Chest X-ray
• TB workup as above
• CMV PCR
• Consider procalcitonin to help distinguish bacterial from other causes

Key Pitfalls to Avoid

1. Do not assume fever is from sarcoidosis flare - The FDA explicitly warns that infections in MMF patients can be fatal 1. Infection must be ruled out first.

2. Do not delay empiric antibiotics if sepsis suspected - While obtaining cultures first is ideal, hemodynamic instability requires immediate broad-spectrum coverage.

3. Consider drug-induced fever from MMF itself - Though rare, MMF can cause acute inflammatory syndrome with fever 3, 4, but this is a diagnosis of exclusion after ruling out infections.

4. Remember that reduced immunosuppression may be needed - The FDA states that reduction in immunosuppression should be considered for patients with new or reactivated viral infections 1, though this must be balanced against sarcoidosis flare risk.